SCHEMBL7180764

SCHEMBL7180764

CCOc1cc(OCC)c(PC(=O)c2c(C)cc(C(C)(C)C)cc2C)c(OCC)c1.[LiH]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
KDM4E B2RXH2 1/20 0.36
RXRA P19793 2/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALDH1A1 P00352 2/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
TSHR P16473 2/20 0.31
RXFP1 Q9HBX9 1/20 0.31
CYP3A4 P08684 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
ESR1 P03372 1/20 0.31
VDR P11473 1/20 0.31
RARG P13631 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180526 0.88 KDM4E (0.38) KDM4ESMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL7188781 0.88 MAPT (0.35) KDM4ERXRASMN1; SMN2ALDH1A1MAPT
SCHEMBL7188930 0.87 FFAR1 (0.34) KDM4ESMN1; SMN2ALDH1A1MAPTVDR
SCHEMBL7184423 0.86 THRB (0.39) RXRARAB9AESR1PPARGELANE
SCHEMBL7182727 0.85 THRB (0.43) TP53TSHRESR1
SCHEMBL7186955 0.84 THRB (0.45) TP53TSHRESR1
SCHEMBL7185529 0.84 KDM4E (0.40) KDM4ERXRARXRBSMN1; SMN2ALDH1A1
SCHEMBL7176059 0.84 FOS (0.34)
SCHEMBL7732347 0.84 F2R (0.33) KDM4EALDH1A1HTTHPGDRAB9A
SCHEMBL7178013 0.84 KDM4E (0.42) EPHX2NR1H4KDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 EPHX2 2476/4885NR1H4 105/4885KDM4E 3226/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 EPHX2 2048/4885NR1H4 149/4885KDM4E 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.